Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Other Accumulated Expenses (2019 - 2020)

Moleculin Biotech's Other Accumulated Expenses history spans 2 years, with the latest figure at $84000.0 for Q4 2020.

  • Quarterly results put Other Accumulated Expenses at $84000.0 for Q4 2020, down 48.78% from a year ago — trailing twelve months through Dec 2020 was $84000.0 (down 48.78% YoY), and the annual figure for FY2020 was $84000.0, down 48.78%.
  • Other Accumulated Expenses for Q4 2020 was $84000.0 at Moleculin Biotech, up from $56000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $164000.0 in Q4 2019 to a low of $56000.0 in Q3 2020.